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OBJECTIVES: According to international guidelines on the management of asthma
(GINA), step down to the lowest dose of treatment that maintains control should be
considered for controlled patients. The aim of this analysis was to estimate the
costs and health outcomes associated with step down of controlled patients on
high dose fluticasone/salmeterol (FP/S 1000/100g daily) dry powder to either ex-
trafine beclometasone/formoterol (BDP/F 400/24g) pMDI or medium dose FP/S
(500/100g) dry powder in the UK setting. METHODS: A patient-level simulation
Markov model was defined to perform the simulation of a cohort of patients along
three comparative arms (FP/S 1000/100, FP/S 500/100, BDP/F 400/24). Transition
probabilities and healthcare resources costs were derived from patient-level data
of a recent multinational clinical trial comparing the three treatments. Direct costs
and health state utilities were sourced from published literature and UK current
prices and tariffs. The analysis was conducted from the UK National Healthcare
System perspective, over a six–month time horizon. Probabilistic sensitivity anal-
ysis was conducted. RESULTS: The analysis showed an ICER (Incremental Cost-
Effectiveness Ratio) of 57,300 GBP/QALY (Quality Adjusted Life Year) associated
with high dose FP/S 1000/100g versus extrafine BDP/F 400/24g and an ICER of
approximately 86,300 GBP/QALY associated with medium dose FP/S 500/100g ver-
sus BDP/F 400/24g. CONCLUSIONS: International guidelines recommend that
when asthma control is achieved and stabilized, treatment can be stepped down to
the lowest possible dose maintaining control. This analysis shows that maintain-
ing controlled patients on high dose FP/S is not a cost-effective strategy. Extrafine
BDP/F 400/24g daily can be considered to be a cost-effective option in the UK to
maintain control of asthmatic patients stepped down from high dose FP/S 1000/
100g daily.
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OBJECTIVES: In order to assess cost-effectiveness of SAL/FP Fen/IB versus Fen/IB
only in chronic obstructive pulmonary disease (COPD) treatment in different Rus-
sian regions we developed PHACTOR pharmacoeconomic model. METHODS: Our
model was based on the constant disease-specific data such as number of COPD
exacerbations and health care resource utilization data obtained from PHACTOR
(multicenter observational research of severe and very severe COPD). The method-
ology of PHACTOR research was published in 13th ISPOR Annual European Con-
gress (Research Abstract #PRS31). The following region-specific input data were
taken into account: drug prices (from the List of Vital and Essential Pharmaceuti-
cals), medical tariffs (from regional government regulations), gross domestic prod-
uct (GDP) per capita and average salary (from statistics service). SAL/FP  Fen/IB
was compared with Fen/IB only. ICERs (cost per COPD exacerbation avoided) were
calculated for all 83 Russian regions. Regional willingness to pay (WTP) was as-
sumed as three regional GDP per capita. RESULTS:Average yearly drug costs varied
from 29,539 RUR (Belgorod) to 35,264 RUR (Yakutia) for SAL/FP  Fen/IB treatment
and from 7,877 RUR (Altai Republic) to 9,442 RUR (Yakutia) for Fen/IB treatment.
Estimated yearly costs of COPD exacerbation treatment significantly varied from
6,552 RUR (Evreyskaya AO) to 63,053 RUR (Chukotka) for SAL/FP Fen/IB treatment
and from 12,592 RUR (Evreyskaya AO) to 109,019 RUR (Chukotka) for Fen/IB treat-
ment. SAL/FP  Fen/IB treatment was cost-saving (dominating) in 9 regions and
cost-effective in 74 regions (ICERWTP; in this regions ICERs were from 74 RUR to
4,605 RUR per COPD exacerbation avoided). CONCLUSIONS: This analysis demon-
strated that regional data had the biggest impact on final cost-effectiveness results.
In general case SAL/FP  Fen/IB treatment was cost-effective in most Russian
regions and cost-saving in some regions.
PRS38
THE COST-EFFECTIVENESS OF ROFLUMILAST FOR COPD IN SWEDEN
Engström A
Nycomed, Stockholm, Sweden
OBJECTIVES: Daxas (roflumilast) is a new PDE4-inhibitor which targets the under-
lying inflammation in COPD. It is indicated for treating severe and very severe
COPD associated with chronic bronchitis and a history of frequent exacerbations.
The objective was to assess the incremental cost-effectiveness of using roflumilast
in a Swedish health care setting.The clinical trials for roflumilast have shown that
it consistently reduces exacerbations by approx. 20% and that it also provides a
lung function benefit of between 46-81 mL in addition to long-acting
bronchodilators. METHODS: A Markov model with a life time time horizon, one
month cycles and a discount rate of 3% was constructed using Treeage and an Excel
interface. The model uses comparator treatments relevant to Swedish guidelines
including long acting -2 agonist (LABA), inhaled corticosteroids (ICS) and long-
acting muscarinic antagonists(LAMA). All input parameters on costs and epidemi-
ology were from Swedish sources. Clinical effectiveness was based on results from
clinical trials along with indirect comparisons to address other comparators rele-
vant to the reimbursement authorities. The analysis had a societal perspective and
included lost productivity using a human capital approach. Outcomes were mea-
sured in QALYs. Uncertainty was addressed both through probabilistic sensitivity
analysis and one-way analyses of central variables. RESULTS: Treatment with ro-
flumilast (ROFL) as an add-on to LABA resulted in an incremental gain of 0.35 QALY.
From a societal perspective the ICER for LABAROFLU versus LABA was €18,000 per
QALY. The probability that LABAROFLU was cost-effective using a €50 000 threshold
was 97%. The ICER for LABAROFLU vs LABAICS was €14,500.
ROFLULAMALABAICS vs LAMALABAICS was €19,000. CONCLUSIONS: The
ICERs calculated were all well below commonly accepted willingness to pay for a
QALY in Sweden for all different comparator scenarios. The results were stable
when central variables were varied. Roflumilast is a cost-effective treatment for
severe and very severe COPD.
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OBJECTIVES: Chronic obstructive pulmonary disease (COPD) represents a consid-
erable burden on patients and health systems. Frequent exacerbations in patients
with COPD result in high healthcare costs. Roflumilast, an oral, selective phos-
phodiesterase-4 inhibitor, has been shown to reduce exacerbation rates and im-
prove lung function in patients with severe COPD. The objective of this analysis is
to estimate the long-term cost and outcomes of roflumilast added to several bron-
chodilator regimens in management of severe COPD from a health payer perspec-
tive in Switzerland. METHODS: A Markov cohort model was constructed to simu-
late the progression of disease, mortality, and exacerbation rates in patients with
COPD. Transition probabilities between severe and very severe COPD were deter-
mined from the published literature. Background mortality was expressed through
the risk of death in the general population and standardised mortality ratios (SMR);
hospital mortality was based on the published literature. A cost-effectiveness anal-
ysis was conducted for roflumilast as add-on treatment to LAMA, LABA/ICS and
LAMALABA/ICS, with the relative ratios of exacerbations rates derived from a
recently published multiple-treatment-comparison. Direct costs were sourced
from published Swiss data; utilities and disutilities of exacerbations were based on
published data. Analysis was conducted from the payer perspective in Switzerland,
for a lifetime horizon, with costs and outcomes discounted at 2.5% pa. A range of
sensitivity analyses were conducted. RESULTS: The added quality-adjusted life
years (QALY) and exacerbations avoided were: (0.275 and 2.56); (0.289 and 2.69); and
(0.278 and 2.59) for roflumilast added to LAMA, LABA/ICS, and LAMALABA/ICS
respectively. The incremental cost-effectiveness ratios (ICER) were CHF 18,512 per
QALY in LAMAroflumilast vs. LAMA, CHF 17,083 per QALY in LABA/ICSroflumilast
vs. LABA/ICS, and CHF 19,470 per QALY in LAMALABA/ICSroflumilast vs.
LAMALABA/ICS. CONCLUSIONS: For patients with severe COPD who continue to
exacerbate in clinical practice in Switzerland roflumilast can be a cost-effective
treatment option.
PRS40
COST-UTILITY OF FLUTICASONE COMPARED WITH BECLOMETHASONE AND
BUDESONID IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN
POLAND
Bolisega D1, Dziewiatka M1, Fedyna M1, Ziobro M1, Rutkowski J1, Haldas M1, Barlog D2,
Dziurda D2, Glogowski C2, Rys P1, Plisko R1
1HTA Consulting, Krakow, Poland, 2GSK, Warszawa, Poland
OBJECTIVES: To evaluate cost-utility of fluticasone compared with beclometha-
sone and budesonide in COPD treatment in Poland. METHODS: A discreet event
simulation (DES) model was used to estimate utilities and costs of treatment (med-
icines, standard hospitalization, ambulatory visit cost for patients with COPD) on
fluticasone therapy in comparison to beclometasone and budesonide. Analysis
was performed from public payer’s perspective with a time horizon of 10 years.
Measures of medical effects of the therapies were obtained from a systematic
review of RCTs. The range of possible outcomes in the model included: exacerba-
tion, death, FEV1. Based on the systematic review fluticasone is more effective than
beclomethasone and budesonide in terms of FEV1 improvement. Differences in
costs and effects are presented per individual patient, described as statistically
significant (SS) or non-significant (NS) and discounted at 5% and 3.5% respectively.
Probabilistic sensitivity analysis was performed to estimate the probability that
fluticasone is cost-effective in Polish conditions (threshold about 105,000
PLN/QALY). RESULTS: The QALY difference between fluticasone and beclometha-
sone was 0.136 QALY (SS), and the cost difference was 4544 PLN (NS). In determin-
istic analysis incremental cost per QALY for fluticasone compared with beclome-
tasone was 33,333 PLN. The probability of fluticasone being cost-effective was
88.1%. The QALY difference between fluticasone and budesonide in 10 years per-
spective was 0.071 (NS). The cost difference was 9,027 PLN (SS). In deterministic
analysis incremental cost per QALY for fluticasone compared with budesonide was
127,190 PLN and exceeded the threshold. There was 44.9% chance that the flutica-
sone therapy was cost-effective in comparison with budesonide therapy.
CONCLUSIONS: Fluticasone therapy is more effective than beclomethasone (SS)
and budesonide (NS). It offers to patients with COPD an additional, pay-off thera-
peutic option.
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